NewGenIvf Group Ltd Chairman & CEO Siu Wing Fung Alfred received a grant of stock options to acquire 56,851 Class B Ordinary Shares at an exercise price of US$0.0001 per share under the company’s 2024 Share Incentive Plan.
The options vest monthly from 4 June 2026 through 4 May 2029, starting with 5,685 options and then 1,462 options on most monthly vesting dates, with 1,458 options vesting in the final tranche. The options expire on 4 May 2033, and following this grant he holds 56,881 stock options directly.
NewGenIvf Group Ltd Chairman & CEO Siu Wing Fung Alfred received a grant of stock options to acquire 56,851 Class B Ordinary Shares at an exercise price of US$0.0001 per share under the company’s 2024 Share Incentive Plan.
The options vest monthly from 4 June 2026 through 4 May 2029, starting with 5,685 options and then 1,462 options on most monthly vesting dates, with 1,458 options vesting in the final tranche. The options expire on 4 May 2033, and following this grant he holds 56,881 stock options directly.
NewGenIvf Group Ltd reported that Chief Marketing Officer Fong Hei Yue Tina received a grant of stock options to acquire 56,851 Class B Ordinary Shares. The options carry an exercise price of US$0.0001 per share and were granted under the company’s 2024 Share Incentive Plan.
The award vests over time: 5,685 options on June 4, 2026, 1,462 options on the 4th day of each month from July 4, 2026 through April 4, 2029, and 1,458 options on May 4, 2029. The options expire on May 4, 2033, and following this grant she holds 56,890 options directly.
NewGenIvf Group Ltd reported that Chief Marketing Officer Fong Hei Yue Tina received a grant of stock options to acquire 56,851 Class B Ordinary Shares. The options carry an exercise price of US$0.0001 per share and were granted under the company’s 2024 Share Incentive Plan.
The award vests over time: 5,685 options on June 4, 2026, 1,462 options on the 4th day of each month from July 4, 2026 through April 4, 2029, and 1,458 options on May 4, 2029. The options expire on May 4, 2033, and following this grant she holds 56,890 options directly.
NewGenIvf Group Limited files its annual report highlighting severe liquidity pressure, heavy dilution risk and a high‑risk diversification strategy beyond fertility services. As of December 31, 2025, cash and cash equivalents were about US$758,621, while US$5,266,000 of convertible promissory notes remained outstanding as of March 30, 2026, raising going concern uncertainty.
The company can draw up to US$100,000,000 under an equity line with White Lion, of which roughly US$15.55 million has already converted to equity, alongside 1,224,328 warrants and 113,703 share-incentive shares that may further dilute holders. NewGenIvf is pivoting from fertility into Solana staking, digital-asset tokenization and UAE real estate, including a planned investment of up to US$30 million in SOL and a novel term sheet to receive up to 600,000 SOL for shares. The firm also details recent Nasdaq listing deficiencies and reliance on repeated reverse stock splits to maintain listing.
NewGenIvf Group Limited files its annual report highlighting severe liquidity pressure, heavy dilution risk and a high‑risk diversification strategy beyond fertility services. As of December 31, 2025, cash and cash equivalents were about US$758,621, while US$5,266,000 of convertible promissory notes remained outstanding as of March 30, 2026, raising going concern uncertainty.
The company can draw up to US$100,000,000 under an equity line with White Lion, of which roughly US$15.55 million has already converted to equity, alongside 1,224,328 warrants and 113,703 share-incentive shares that may further dilute holders. NewGenIvf is pivoting from fertility into Solana staking, digital-asset tokenization and UAE real estate, including a planned investment of up to US$30 million in SOL and a novel term sheet to receive up to 600,000 SOL for shares. The firm also details recent Nasdaq listing deficiencies and reliance on repeated reverse stock splits to maintain listing.
NewGenIvf Group Ltd director and executive Alfred Siu Wing Fung, who serves as Chairman & CEO, has filed an initial Form 3 reporting his beneficial ownership in the company. The filing shows he holds 30 Class B Ordinary Shares, reported as direct ownership, with no buy or sell transactions disclosed.
NewGenIvf Group Ltd director and executive Alfred Siu Wing Fung, who serves as Chairman & CEO, has filed an initial Form 3 reporting his beneficial ownership in the company. The filing shows he holds 30 Class B Ordinary Shares, reported as direct ownership, with no buy or sell transactions disclosed.
NewGenIvf Group Ltd director Au Hok Man Jefferson has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. This filing establishes his status as a director at NewGenIvf, and the accompanying data show no insider buy, sell, or derivative transactions reported in this Form 3.
NewGenIvf Group Ltd director Au Hok Man Jefferson has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. This filing establishes his status as a director at NewGenIvf, and the accompanying data show no insider buy, sell, or derivative transactions reported in this Form 3.
NewGenIvf Group Ltd Chief Financial Officer Chan Chung Ho has filed an initial insider ownership report on Form 3 for the company’s ordinary shares. The filing lists him as an officer with the title Chief Financial Officer and does not report any insider transactions in the available data.
NewGenIvf Group Ltd Chief Financial Officer Chan Chung Ho has filed an initial insider ownership report on Form 3 for the company’s ordinary shares. The filing lists him as an officer with the title Chief Financial Officer and does not report any insider transactions in the available data.
NewGenIvf Group Limited is implementing a reverse stock split of all issued and unissued shares at a ratio of one new share for every four existing shares. This affects Class A and Class B ordinary shares and preferred shares.
The reverse split will be effective at 12:01 a.m. ET on March 16, 2026, and Class A ordinary shares will begin trading on Nasdaq on a split-adjusted basis that day, continuing under the symbol NIVF with a new CUSIP G0544E147. The number of outstanding Class A ordinary shares will change from 2,273,790 to approximately 568,323 shares. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one whole share. Options, warrants and other convertible securities will be adjusted by dividing their underlying share amounts by four.
NewGenIvf Group Limited is implementing a reverse stock split of all issued and unissued shares at a ratio of one new share for every four existing shares. This affects Class A and Class B ordinary shares and preferred shares.
The reverse split will be effective at 12:01 a.m. ET on March 16, 2026, and Class A ordinary shares will begin trading on Nasdaq on a split-adjusted basis that day, continuing under the symbol NIVF with a new CUSIP G0544E147. The number of outstanding Class A ordinary shares will change from 2,273,790 to approximately 568,323 shares. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one whole share. Options, warrants and other convertible securities will be adjusted by dividing their underlying share amounts by four.
NewGenIvf Group Limited is implementing a reverse stock split of all issued and unissued shares at a ratio of one new share for every three existing shares. This affects Class A ordinary shares, Class B ordinary shares and preferred shares and was approved by the board under BVI law without a shareholder vote.
The reverse split will be effective at 12:01 a.m. (ET) on January 26, 2026, with Class A ordinary shares beginning Nasdaq trading on a split-adjusted basis the same day under the symbol NIVF and a new CUSIP. The number of outstanding Class A ordinary shares will change from 2,948,080 to approximately 982,694, with every three pre-split shares automatically becoming one post-split share. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one full share. Outstanding options, warrants and other convertible securities will be adjusted by dividing the underlying share amounts by three.
NewGenIvf Group Limited is implementing a reverse stock split of all issued and unissued shares at a ratio of one new share for every three existing shares. This affects Class A ordinary shares, Class B ordinary shares and preferred shares and was approved by the board under BVI law without a shareholder vote.
The reverse split will be effective at 12:01 a.m. (ET) on January 26, 2026, with Class A ordinary shares beginning Nasdaq trading on a split-adjusted basis the same day under the symbol NIVF and a new CUSIP. The number of outstanding Class A ordinary shares will change from 2,948,080 to approximately 982,694, with every three pre-split shares automatically becoming one post-split share. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one full share. Outstanding options, warrants and other convertible securities will be adjusted by dividing the underlying share amounts by three.